Growth hormone deficiency studies recruiting patients need your help. Receive premium care & cutting edge treatments by enrolling in clinical trials today.

Top 10 Growth Hormone Deficiency Trials [2023 Studies] | Power

Growth Hormone Deficiency Clinical Trials

Growth Hormone Deficiency studies recruiting patients for novel treatments. Filter by phase, distance, and inclusion criteria to find your perfect clinical trial.

Pivotal Trial

No Placebo-Only Group

The purpose of this study is to evaluate the efficacy and safety of weekly GenSci004 compared with daily Genotropin in treatment-naive children with growth failure due to GHD.

A Study to Investigate Efficacy and Safety of Weekly PEG-somatropin (GenSci004) in Treatment Naive Children With Growth Hormone Deficiency

PEG-somatropin for Growth Hormone Deficiency

You have previously been treated with rhGH (recombinant human growth hormone), long-acting growth hormones, or IGF-1 therapy.

A written, signed agreement from the participant's parent(s) or legal guardian(s), as well as the participant's own consent in writing, is required.

You have a height which is at least two standard deviations below the mean for your age and gender.

Your body mass index is within two standard deviations of the average BMI for your age and gender.

Your growth hormone stimulation tests are no greater than 10 ng/mL.

Your baseline IGF 1 level is at least one standard deviation below the mean for your age and gender (IGF 1 SDS ≤-1.0).

Children with multiple hormonal insufficiencies must have been receiving concurrent hormone replacement therapy for other endocrine pathways for at least 3 months.

You are a prepubertal child in Tanner Stage 1 with Growth Hormone Deficiency.

GenSci004

Genotropin

This is a multi-national trial. The trial aims to study the long-term safety of LUM-201 in subjects with Idiopathic Pediatric Growth Hormone Deficiency (iPGHD). This study will also assess pharmacodynamics and efficacy response to therapy with LUM-201.

A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)

LUM-201 for Growth Hormone Deficiency

You have taken part in a previous study for pediatric LUM-201 GHD and completed at least the 12-month visit, and you can continue treatment if you meet all other requirements.

You are taking certain medications that can affect how LUM-201 is processed in your body for a long time. If you're taking these medications for a shorter time, the study doctor will decide if you can still participate.

LUM-201

This is a phase 3 open-label multicenter extension study designed to evaluate the long-term safety and efficacy of Lonapegsomatropin administered once-weekly. The study participants are adults (males and females) with confirmed growth hormone deficiency (GHD) having completed the treatment period in study TCH-306 (foresiGHt).

A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

Lonapegsomatropin for Growth Hormone Deficiency

You are taking diabetes medications other than metformin or DPP-4 inhibitors.

At Visit 7 in trial TCH-306, you have no signs of increased pressure inside your head or advanced diabetic eye problems during an eye exam.

You have had a bad reaction to the study drug somatropin or its ingredients in the past.

Your diabetes is not well controlled, with a high HbA1C level above 7.5%.

You have cancer that is currently growing, or you have had cancer in the past, except for certain types of skin and cervix cancers that have been completely removed.

Growth Hormone Deficiency Clinical Trials

GenSci004for Growth Hormone Deficiency

LUM-201 (1.6 Mg/kg/day)for Human Growth Hormone Deficiency

Lonapegsomatropinfor Growth Hormone Deficiency